GRAN® / Peglasta® / Neulasta®
GRAN® (Filgrastim) is a human colony-stimulating factor (G-CSF) produced by genetic recombination technology. It works to selectively increase the count of a type of white blood cell called neurotrophil, as well as increase their functional efficacy. This enables a quick recovery from neutropenia occurring as a result of cancer chemotherapy and reduces the risk of infection, allowing for more effective chemotherapy. It also acts to relieve congenital neutropenia or neutropenia occurring after hematopoietic stem-cell transplantation (such as bone-marrow transplants). It received additional approval for application to PBSCT (peripheral blood stem cell transfusion) mobilization as well.
In Asia, Kyowa Hakko Kirin have marketed pegfilgrastim as G-LASTA® /Peglasta® /Neulasta® for chemotherapy-induced febrile neutropenia.
The Information on this website regarding Neulasta®, Filgrastim and Pegfilgrastim is not intended for audiences outside of, or to imply indications not approved in, the countries listed below. Neulasta® is a registered trademark of Amgen Inc.